1. Home
  2. BMEA vs GDO Comparison

BMEA vs GDO Comparison

Compare BMEA & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.54

Market Cap

107.7M

Sector

Health Care

ML Signal

HOLD

Logo Western Asset Global Corporate Defined Opportunity Fund Inc.

GDO

Western Asset Global Corporate Defined Opportunity Fund Inc.

HOLD

Current Price

$10.83

Market Cap

86.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMEA
GDO
Founded
2017
N/A
Country
United States
United States
Employees
41
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
107.7M
86.7M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
BMEA
GDO
Price
$1.54
$10.83
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$8.86
N/A
AVG Volume (30 Days)
1.3M
27.8K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
69.19
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$10.29
52 Week High
$3.07
$12.15

Technical Indicators

Market Signals
Indicator
BMEA
GDO
Relative Strength Index (RSI) 62.69 42.93
Support Level $1.22 N/A
Resistance Level $1.66 $11.71
Average True Range (ATR) 0.13 0.15
MACD 0.03 0.02
Stochastic Oscillator 86.54 58.49

Price Performance

Historical Comparison
BMEA
GDO

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.

Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.

Share on Social Networks: